Dexamethasone
- Generic Name
- Dexamethasone
- Brand Names
- Baycadron, Ciprodex, Decadron, Dexamethasone Intensol, Dextenza, Dioptrol, Hexadrol, Hidex 6-day Taper, Maxidex, Maxitrol, Neofordex, Ozurdex, Taperdex 12 Day Taper, Taperdex 6 Day Taper, Taperdex 7-day Taper, Tobradex, Zcort 7 Day Taper
- Drug Type
- Small Molecule
- Chemical Formula
- C22H29FO5
- CAS Number
- 50-02-2
- Unique Ingredient Identifier
- 7S5I7G3JQL
- Background
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like hydrocortisone and prednisolone.
Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
- Indication
Dexamethasone and ciprofloxacin otic suspension is indicated for bacterial infections with inflammation in acute otitis media and acute otitis externa. Intramuscular and intravenous injections are indicated for a number of endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Oral tablets are indicated for the treatment of multiple myeloma. An intravitreal implant is indicated for some forms of macular edema and non-infectious posterior uveitis affecting the posterior of the eye. Various ophthalmic formulations are indicated for inflammatory conditions of the eye.
- Associated Conditions
- Acute Gouty Arthritis, Acute Leukemia, Acute Otitis Externa, Acute Otitis Media (AOM), Adrenocortical Hyperfunction, Adrenocortical Insufficiency, Allergic Conjunctivitis (AC), Alopecia Areata (AA), Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Berylliosis, Bullous dermatitis herpetiformis, Bursitis, Chorioretinitis, Choroiditis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Conjunctivitis, Contact Dermatitis, Cushing's Syndrome, Dermatitis, Diabetic Macular Edema (DME), Discoid Lupus Erythematosus (DLE), Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Episcleritis, Erythroblastopenia, Eye Infections, Eye allergy, Glaucoma, Hypercalcemia, Immune Thrombocytopenia (ITP), Infection, Inflammation, Inflammation of the External Auditory Canal, Intraocular Inflammation, Iridocyclitis, Iritis, Keloids Scars, Keratitis, Lichen Planus (LP), Lichen simplex chronicus, Loeffler's syndrome, Lymphoma, Macular Edema, Meningitis caused by Mycobacterium Tuberculosis, Middle ear inflammation, Mucosal Inflammation of the eye, Multiple Myeloma (MM), Muscle Inflammation caused by Cataract Surgery of the eye, Mycosis Fungoides (MF), Necrobiosis lipoidica diabeticorum, Non-infectious Posterior Uveitis, Ocular Infections, Irritations and Inflammations, Ocular Inflammation, Ocular Inflammation and Pain, Ocular Irritation, Ocular Itching, Ophthalmia, Sympathetic, Optic Neuritis, Otitis Externa, Pemphigus, Perennial Allergic Rhinitis (PAR), Phlyctenular keratoconjunctivitis, Postoperative Infections of the eyes caused by susceptible bacteria, Posttraumatic Osteoarthritis, Regional Enteritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Rosacea, Sarcoidosis, Scleritis, Seasonal Allergic Rhinitis, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Stevens-Johnson Syndrome, Synovitis, Systemic Lupus Erythematosus, Tenosynovitis, Trichinosis, Tuberculosis (TB), Ulcerative Colitis, Uveitis, Vernal Keratoconjunctivitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Anterior eye segment inflammation, Corticosteroid-responsive dermatoses, Ear infection-not otherwise specified caused by susceptible bacteria, Exfoliative erythroderma, Granuloma annulare lesions, Non-suppurative Thyroiditis, Ocular bacterial infections, Severe Psoriasis, Steroid-responsive inflammation of the eye, Swelling of the eyes, Varicella-zoster virus acute retinal necrosis, Watery itchy eyes
- Associated Therapies
- -
Two Combination Chemotherapy Regimens in Treating Children With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2008-06-30
- Last Posted Date
- 2020-03-05
- Lead Sponsor
- Prince of Wales Hospital, Shatin, Hong Kong
- Target Recruit Count
- 2231
- Registration Number
- NCT00707083
- Locations
- ๐จ๐ณ
Prince of Wales Hospital, Hong Kong, China
๐จ๐ณQueen Mary Hospital - Hong Kong, Hong Kong, China
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
- Conditions
- Refractory Multiple MyelomaStage I Multiple MyelomaStage II Multiple MyelomaStage III Multiple Myeloma
- Interventions
- First Posted Date
- 2008-06-09
- Last Posted Date
- 2015-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 15
- Registration Number
- NCT00693433
- Locations
- ๐บ๐ธ
Veteran's Administration Medical Center, Las Angeles, California, United States
Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- First Posted Date
- 2008-06-02
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 13
- Registration Number
- NCT00687674
- Locations
- ๐บ๐ธ
Mayo Clinic, Rochester, Minnesota, United States
Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease
- Conditions
- Oral Chronic Graft-versus-host Disease
- Interventions
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2014-03-20
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 46
- Registration Number
- NCT00686855
- Locations
- ๐บ๐ธ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธMassachusetts General Hospital, Boston, Massachusetts, United States
๐บ๐ธChildren's Hospital Boston, Boston, Massachusetts, United States
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2008-05-16
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Boston Medical Center
- Target Recruit Count
- 16
- Registration Number
- NCT00679367
- Locations
- ๐บ๐ธ
Boston University Cancer Research Center, Boston, Massachusetts, United States
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia
- Conditions
- LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2008-05-05
- Last Posted Date
- 2020-12-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 220
- Registration Number
- NCT00671658
- Locations
- ๐บ๐ธ
UT MD Anderson Cancer Center, Houston, Texas, United States
Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
- Conditions
- Acute Lymphoblastic LeukemiaAdult B Acute Lymphoblastic LeukemiaChildhood B Acute Lymphoblastic Leukemia
- Interventions
- Drug: Calaspargase Pegol-mknlDrug: CyclophosphamideDrug: CytarabineDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: Doxorubicin HydrochlorideOther: Laboratory Biomarker AnalysisDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseOther: Pharmacological StudyDrug: PrednisoneRadiation: Radiation TherapyDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2008-05-02
- Last Posted Date
- 2021-04-27
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 166
- Registration Number
- NCT00671034
- Locations
- ๐บ๐ธ
Connecticut Children's Medical Center, Hartford, Connecticut, United States
๐บ๐ธUniversity of Connecticut, Farmington, Connecticut, United States
๐บ๐ธUniversity of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma
- Conditions
- Burkitt's LymphomaBurkitt'S-like Lymphoma
- Interventions
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 56
- Registration Number
- NCT00669877
- Locations
- ๐บ๐ธ
The University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States
Efficacy and Safety of a Single Dose of Canakinumab (ACZ885) in Hospitalized Patients With Acute Gout
- Conditions
- Arthritis, Gouty
- Interventions
- Biological: canakinumabDrug: dexamethasoneOther: placebo matching dexamethasoneOther: placebo matching canakinumab
- First Posted Date
- 2008-04-22
- Last Posted Date
- 2013-01-07
- Lead Sponsor
- Novartis
- Target Recruit Count
- 6
- Registration Number
- NCT00663169
- Locations
- ๐ฌ๐ง
Novartis Investigator Site, Glasgow, United Kingdom
Prednisone or Dexamethasone in Newly Diagnosed, Previously Untreated Primary Immune Thrombocytopenic Purpura
- Conditions
- Nonneoplastic Condition
- Interventions
- First Posted Date
- 2008-04-14
- Last Posted Date
- 2017-02-20
- Target Recruit Count
- 150
- Registration Number
- NCT00657410
- Locations
- ๐ฎ๐น
S.O.C. di Ematologia - Azienda Ospedaliera - SS. Antonio e Biagio e Cesare Arrigo, Alessandria, Italy
๐ฎ๐นUSL 8 - Ospedale S.Donato, Arezzo, Italy
๐ฎ๐นUO Ematologia con trapianto- AOU Policlinico Consorziale di Bari, Bari, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.